Eurobio Scientific and Vivo Medical Group enter into exclusive negotiations for the acquisition of two companies in the United Kingdom


You May Also Like

CytomX Therapeutics Presents CX-072 Clinical Translational Data at 2018 SITC Annual Meeting

 - Demonstrates Further Proof-of-Mechanism of Probody™ Platform – - Consistent with CX-072 Clinical Observations ...

OSE Immunotherapeutics Reports First-Half 2018 Results and Provides a Corporate Update

Key Highlights: Entered into a global immuno-oncology agreement in April 2018 with Boehringer Ingelheim ...